Read The Fine Print: China's New Data Protection Plan Has Some Catches
Executive Summary
China SDA's newest proposal gives six and 12 years' data protection for innovative new drugs and therapeutic biologics, respectively, but certain terms and conditions apply.
You may also be interested in...
Cancer, Orphan, Pediatric Drug Developers Join China Foreign Data Acceptance Party
China officially issues regulation accepting clinical data obtained from overseas studies, with a priority on treatments for critical, rare and pediatric conditions.
China Rings In New Year With Major Deals, Record IPOs And Trends To Watch
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One Year On: WHO Probe In Wuhan, Mixed Vaccine Results For Sinovac
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: